Find Clinical Trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Cancers |
| Indication | Cholangiocarcinoma |
| Sponsor | Institut de Recherches Internationales Servier |
| Active substance/ Medical device |
AG120, Ivosidenib |
| Active Substance Code | AG-120 |
| Protocol Code | AG120-C-005 |
| EudraCT Code | 2015‐005117-72 |
| NCT Code | NCT02989857 |
Documents and links
| Lay summary | |
| First results summary | READ MORE  |
| Second results summary | READ MORE |
| Third results summary | READ MORE |
| Scientific publication | READ MORE |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
